# US 2004/0081663 A1 · Pharmaceutical composition for treatment and prevention of cancer and the preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081663 A1
- Document ID: US20040081663A1
- Status: Published application
- Kind: A1
- Application number: 10/443,801
- Filed: 2003-05-23
- Published: 2004-04-29
- Earliest claimed: 2002-10-25
- Inventors: Chun-Min Chang; Ming-Da Hu; Chien-Yang Li; Chih-Chung Yeh
- Web page: https://patentgrep.com/patent/US20040081663A1

## CPC

- A61K 36/062: Ascomycota
- C12N 1/14: Fungi (culture of mushrooms A01G18/00; as new plants A01H15/00); Culture media therefor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A composition for treatment and prevention of cancer including a Monascus fermentation extract as active component. The inventive Monascus extract is produced by liquid fermentation, and includes at least one component with three characteristic ultraviolet absorption peaks at 230, 237 and 246 nm.

## Claims

### Claim 1

A composition of Monascus extract with at least one component with three characteristic ultraviolet absorption peaks at 230, 237 and 246 nm.

### Claim 2 (depends on 1)

The composition as claimed in claim 1, wherein the Monascus extract comprises a component having an identifying characteristic of a retention time of 7.7 min. on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250mm) and elution with methanol-water-H3PO4 (3.2 L:0.8 L:1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 3 (depends on 2)

The composition as claimed in claim 2, wherein the Monascus extract comprises two components having identifying characteristics of retention time of 6.6 and 8.7 min. respectively on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250mm) and elution with methanol-water-H3PO4 (3.2 L: 0.8 L: 1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 4 (depends on 1)

The composition as claimed in claim 1, wherein the Monascus extract comprises two components having identifying characteristics of retention time of 7.7 and 8.7 min. respectively on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250mm) and elution with methanol-water-H3PO4 (3.2 L: 0.8 L: 1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 5 (depends on 4)

The composition as claimed in claim 4, wherein the Monascus extract comprises two components having identifying characteristics of retention time of 9.9 and 12 min. respectively on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250 mm) and elution with methanol-water-H3PO4 (3.2 L:0.8 L:1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 6 (depends on 1)

The composition as claimed in claim 1, wherein the Monascus extract comprises lovastatin.

### Claim 7 (depends on 1)

The composition as claimed in claim 1, wherein the Monascus extract is a fermentation product of Monascus purpureus Went, Monascus ruber van Tieghem, Monascus pilosus Sato, Monascus albidus Sato Monascus pubigerus Sato, Monascus floridanus, Monascus sanguineus, Monascus kaoliang or Monascus albus.

### Claim 8 (depends on 1)

The composition as claimed in claim 1, wherein the Monascus extract is a fermentation product of strain ATCC No. 16360, ATCC No. 16363, ATCC No. 16364, ATCC No. 16368, ATCC No. IFO4520, ATCC No. 22080, ATCC No. 16385, ATCC No. 16427, ATCC No. 15670, ATCC No. 16246, ATCC No.18199, ATCC No. 36928, ATCC No. 16365, CCRC No. 31499, CCRC No. 31502, CCRC No. 31503, CCRC No. 31505, CCRC No. 31526, CCRC No. 31527, CCRC No. 31529, CCRC No. 31530, CCRC No. 31532, CCRC No. 31533, CCRC No. 31535, CCRC No. 31540, or CCRC No. 31542.

### Claim 9

A pharmaceutical composition for treatment and prevention of cancer, comprising:
a Monascus composition, comprising at least one component with three characteristic ultraviolet absorption peaks at 230, 237 and 246 nm; and
a pharmaceutically acceptable carrier or excipient.

### Claim 10 (depends on 9)

The pharmaceutical composition as claimed in claim 9, wherein the Monascus composition comprises a component having an identifying characteristic of a retention time of 7.7 min. on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250 mm) and elution with methanol-water-H3PO4 (3.2 L:0.8 L:1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 11 (depends on 10)

The pharmaceutical composition as claimed in claim 10, wherein the Monascus composition comprises two components having identifying characteristics of retention time of 6.6 and 8.7 min. respectively on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250mm) and elution with methanol-water-H3PO4 (3.2 L:0.8 L:1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 12 (depends on 11)

The pharmaceutical composition as claimed in claim 11, wherein the Monascus composition comprises two components having identifying characteristics of retention time of 9.9 and 12 min. respectively on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250 mm) and elution with methanol-water-H3PO4 (3.2 L:0.8 L:1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 13 (depends on 9)

The pharmaceutical composition as claimed in claim 9, wherein the Monascus composition comprises lovastatin.

### Claim 14 (depends on 9)

The pharmaceutical composition as claimed in claim 9, wherein the Monascus composition is an fermentation product of Monascus purpureus Went, Monascus ruber van Tieghem, Monascus pilosus Sato, Monascus albidus Sato Monascus pubigerus Sato, Monascus floridanus, Monascus sanguineus, Monascus kaoliang or Monascus albus.

### Claim 15 (depends on 9)

The pharmaceutical composition as claimed in claim 9, wherein the Monascus composition is an fermentation product of strain ATCC No. 16360, ATCC No. 16363, ATCC No. 16364, ATCC No. 16368, ATCC No. IF04520, ATCC No. 22080, ATCC No. 16385, ATCC No. 16427, ATCC No. 15670, ATCC No. 16246, ATCC No.18199, ATCC No. 36928, ATCC No. 16365, CCRC No. 31499, CCRC No. 31502, CCRC No. 31503, CCRC No. 31505, CCRC No. 31526, CCRC No. 31527, CCRC No. 31529, CCRC No. 31530, CCRC No. 31532, CCRC No. 31533, CCRC No. 31535, CCRC No. 31540, or CCRC No. 31542.

### Claim 16 (depends on 9)

The pharmaceutical composition as claimed in claim 9, wherein the Monascus composition is effective for treating lung cancer or breast cancer.

### Claim 17 (depends on 9)

The pharmaceutical composition as claimed in claim 9, wherein the Monascus composition is a solid fermentation product of rice fermented with a Monascus strain.

### Claim 18 (depends on 9)

The pharmaceutical composition as claimed in claim 9, wherein the Monascus composition is a liquid fermentation product of a Monascus strain.

### Claim 19 (depends on 9)

A method for producing a Monascus composition as claimed in claim 9, the method comprising:
providing a liquid culture medium of grain/starch:peptone:MgSO4.7H2O:water=1-7 g: 0.5-3 g: 0.1-1 g: 100 g;
culturing a Monascus strain in the liquid culture medium at a temperature of about 20 to 35° C., an agitation rate of 100 to 400 rpm, and an aeration rate of 0.1 to 1 vvm for 4 to about 12 days; and
filtering the liquid culture medium to obtain a Monascus extract.

### Claim 20 (depends on 19)

The method as claimed in claim 19, wherein the liquid culture medium further comprises glycerin in a concentration of 10 ml or below.

### Claim 21 (depends on 19)

The method as claimed in claim 19, wherein the liquid culture medium further comprises glucose in a concentration of 6 g or below.

### Claim 22 (depends on 19)

The method as claimed in claim 19, wherein the liquid culture medium further comprises a malt extract in a concentration of 3 g or below.

### Claim 23 (depends on 19)

The method as claimed in claim 19, wherein the liquid culture medium further comprises casein in a concentration of 5 g or below.

### Claim 24 (depends on 19)

The method as claimed in claim 19, wherein the Monascus strain is cultured at about 25° C.

### Claim 25 (depends on 19)

The method as claimed in claim 19, wherein the Monascus strain is cultured at 0.5 vvm aeration rate.

### Claim 26 (depends on 19)

The method as claimed in claim 19, wherein the Monascus strain is cultured for about 14 days.

### Claim 27 (depends on 19)

The method as claimed in claim 19, wherein the Monascus strain is Monascus purpureus Went Monascus ruber van Tieghem Monascus pilosus Sato Monascus albidus Sato Monascus pubigerus Sato Monascus floridanus Monascus sanguineus Monascus kaoliang or Monascus albus.

### Claim 28 (depends on 19)

The method as claimed in claim 19, wherein the Monascus strain is strain ATCC No. 16360, ATCC No. 16363, ATCC No. 16364, ATCC No. 16368, ATCC No. IF04520, ATCC No. 22080, ATCC No. 16385, ATCC No. 16427, ATCC No. 15670, ATCC No. 16246, ATCC No.18199, ATCC No. 36928, ATCC No. 16365, CCRC No. 31499, CCRC No. 31502, CCRC No. 31503, CCRC No. 31505, CCRC No. 31526, CCRC No. 31527, CCRC No. 31529, CCRC No. 31530, CCRC No. 31532, CCRC No. 31533, CCRC No. 31535, CCRC No. 31540, or CCRC No. 31542.

### Claim 29

A method for preventing or treating cancer in a mammal which comprises administrating to the mammal a sufficient amount of a Monascus composition.

### Claim 30 (depends on 9)

The method as claimed in claim 9, wherein the cancer is lung cancer or breast cancer.

### Claim 31 (depends on 9)

The method as claimed in claim 9, wherein the Monascus composition comprises at least one component with three characteristic ultraviolet absorption peaks at 230, 237 and 246 nm.

### Claim 32 (depends on 31)

The method as claimed in claim 31, wherein the Monascus composition comprises a component having an identifying characteristic of a retention time of 7.7 min. on HPLC using a Cosmosil 5C18-ARII column (4.6.times.250mm) and elution with methanol-water-H3PO4 (3.2 L:0.8 L:1.6 ml) at a flow rate of 1 ml/min and detected with 237 nm.

### Claim 33 (depends on 32)

The method as claimed in claim 32, wherein the Monascus composition is an fermentation product of Monascus purpureus Went, Monascus ruber van Tieghem, Monascus pilosus Sato, Monascus albidus Sato Monascus pubigerus Sato, Monascus floridanus, Monascus sanguineus, Monascus kaoliang or Monascus albus.
